NEUROPHYSIOLOGY 2021: Therapeutic effect of novel antidepressant drugs interfering with receptors of neurotransmitters and neuropeptides- Euro Akademie Pobneck, Germany

Major depression is a frequent psychiatric disease, which is mainly treated by different antidepressant drugs. However, one third of the depressive patients remain treatment-resistant. In major depression, in the brainstem, hippocampus and prefrontal cortex, alterations of neurotransmitters and neuropeptides and the belonging neural networks are updated. Starting from these findings, novel antidepressant drugs and combination of different antidepressant drugs are suggested. In the prefrontal cortex, glutamatergic neurons, which receive a postsynaptic excitatory potential from D2 dopaminergic neurons, exert a presynaptic inhibition upon M1 muscarinic cholinergic neurons via NMDA receptors. Medium spiny GABAergic/somatostatin neurons

Author(s): Felix-Martin Werner

Abstract | PDF

Share This Article